Form 4: Protara Therapeutics VP, Controller Hannah Fry Reports Stock Transaction

Hannah Fry, VP and Controller at Protara Therapeutics, sold 394 shares of common stock to cover tax obligations related to a vested stock award.

Summary

• Hannah Fry, the VP and Controller of Protara Therapeutics, reported a transaction involving the company's common stock.
• On January 3, 2025, Ms. Fry disposed of 394 shares of common stock at a price of $6.14 per share.
• This transaction was to cover income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to her on January 3, 2022.
• Following the transaction, Ms. Fry directly owns 29,442 shares of Protara Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing for an insider stock transaction, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine Form 4 filing, which is common for company insiders when they transact in their company's stock. It provides transparency into insider transactions.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is typical for executives who receive stock-based compensation, where shares are often sold to cover tax liabilities upon vesting.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small sale of shares by an executive to cover tax obligations.

Key Dates

Keywords

Protara Therapeutics, stock transaction, insider trading, Form 4, Hannah Fry, executive compensation, restricted stock units